Alliqua, a provider of advanced wound care products, will launch its Biovance human amniotic membrane allograft product at the spring 2014 Symposium on Advanced Wound Care in Orlando, April 23-27.
Biovance is intended for use in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types. It was developed by and is currently being manufactured through a supply agreement with Celgene Cellular Therapeutics.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws